Ir para o conteúdo principal
Olema reports four KAT6A degraders in breast cancer
Image for illustrative purposes only. Not a real photo.

Olema reports four KAT6A degraders in breast cancer

Por

Pontos principais

  • Olema reported preclinical results for four selective KAT6A protein degraders, OP-1 through OP-4, showing near-complete target degradation in estrogen receptor-positive, HER2-negative breast cancer models.
  • The compounds produced tumor regression in T47D models and slowed tumour growth in MCF7 and ST941 models, including models with mutant and wild-type ESR1.
  • The findings will be presented on November 18, 2026, at the EORTC-NCI-AACR Symposium in Barcelona, as Olema explores the potential for oral, once-daily treatment.

Olema Pharmaceuticals (NASDAQ:OLMA) reported preclinical results for four selective KAT6A protein degraders, OP-1 through OP-4, demonstrating antitumour activity in estrogen receptor-positive, HER2-negative breast cancer models.

All four compounds produced near-complete KAT6A degradation with minimal effects on other targets and inhibited cancer cell proliferation in models with both mutant and wild-type ESR1.

In animal studies, the degraders produced tumour regression in T47D models and slowed tumour growth in MCF7 and ST941 models when administered as standalone treatments.

The compounds were well tolerated across implanted-tumour study groups and showed oral absorption in preclinical testing, which Olema said could support the development of once-daily dosing in humans.

Olema is a clinical-stage biotechnology company developing targeted treatments for breast cancer, with its existing pipeline including palazestrant and OP-3136, an investigational oral KAT6A/B inhibitor currently undergoing Phase 1 clinical evaluation.

The company is scheduled to present the KAT6A degrader findings on November 18 at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, providing additional preclinical evidence for its breast cancer research programme.


Perguntas frequentes